Tutorials › Econometrics (Graduate) › Deriving the Complier Average Causal Effect

Potential Outcomes and Experiments · Tutorial 626 of 952

Deriving the Complier Average Causal Effect

See why, under random assignment, exclusion, and monotonicity, the assignment effect on outcomes divided by its effect on treatment receipt identifies the average treatment effect for compliers.

Intermediate 10 min read

What You'll Learn

  • Define the complier average causal effect using potential outcomes for treatment receipt and outcomes.
  • State the assumptions needed to identify the complier effect from randomized assignment.
  • Derive the assignment effect on outcomes as the complier share times the complier effect.
  • Derive the first-stage effect on treatment receipt as the complier share.
  • Form the Wald ratio and interpret its units and target population.
  • Distinguish the population identification result from its sample estimate.

Why Assignment Can Reveal an Effect for Compliers

In a randomized experiment, assignment to an offer or encouragement can be randomized even when treatment receipt is not. Some people assigned to the offer may not take up treatment, while some assigned to the control condition may obtain it. Comparing outcomes by actual treatment receipt can therefore lose the protection of random assignment. The assignment itself, however, remains randomized.

The key result in this tutorial is that, under specific assumptions, the effect of assignment on the outcome divided by the effect of assignment on treatment receipt identifies the complier average causal effect (CACE). The ratio adjusts the assignment effect for the fact that assignment changes treatment receipt only for some individuals. The derivation also clarifies which causal effect this ratio targets—and which assumptions make that interpretation possible.

Potential Outcomes and the Target Effect

Let \(Z_i\in\{0,1\}\) denote individual \(i\)'s randomized assignment, where \(Z_i=1\) is assignment to the offer or encouragement and \(Z_i=0\) is assignment to control. Let \(D_i(z)\in\{0,1\}\) be the treatment receipt that individual \(i\) would have under assignment \(z\). Let \(Y_i(d)\) be the outcome individual \(i\) would have under treatment receipt \(d\). The observed receipt and outcome are \(D_i=D_i(Z_i)\) and \(Y_i=Y_i(D_i)\).

An individual's compliance type is determined by the pair \((D_i(0),D_i(1))\). A complier has \((0,1)\): they receive treatment if assigned to the offer and do not receive it if assigned to control. An always-taker has \((1,1)\), and a never-taker has \((0,0)\). A defier has \((1,0)\). Monotonicity, stated below, rules out defiers.

Definition: The complier average causal effect is the average effect of treatment receipt among individuals who would receive treatment if assigned to the offer and would not receive it if assigned to control: $$ \tau_C = E\!\left[Y_i(1)-Y_i(0)\mid D_i(0)=0,\ D_i(1)=1\right]. $$ It is an average treatment effect for the complier subgroup, not necessarily for the entire randomized population.

The causal effect in this definition is the effect of receiving treatment, not the effect of being assigned to the offer. The distinction matters because assignment and receipt differ for individuals who do not comply with their assignment.

Assumptions for the Derivation

The following conditions are used to connect randomized assignment to the CACE. They concern the design, the relationship between assignment and outcomes, and how assignment changes receipt.

  • Random assignment and positivity. Assignment is independent of the joint collection of potential receipts and outcomes, \(\{D_i(0),D_i(1),Y_i(0),Y_i(1)\}\), and each assignment arm has positive probability. Thus, the two assignment groups represent the same distribution of these potential quantities in expectation.
  • Consistency and SUTVA. Each individual's observed receipt and outcome equal their potential receipt and outcome under the assignment and treatment actually received. There are no relevant multiple versions of treatment or interference between individuals.
  • Exclusion restriction. Assignment affects the outcome only through treatment receipt. In particular, the outcome under assignment \(z\) is \(Y_i(D_i(z))\); there is no additional direct effect of \(Z_i\) on the outcome.
  • Monotonicity. \(D_i(1)\geq D_i(0)\) for every individual. Assignment to the offer does not cause anyone who would otherwise receive treatment to stop receiving it. This rules out defiers.
  • Relevance. Assignment changes treatment receipt in the population. Under monotonicity, this requires a strictly positive proportion of compliers.

Randomization and consistency let us express differences between assignment groups as differences in potential quantities. Exclusion lets us write outcomes as depending on receipt rather than directly on assignment. Monotonicity then makes the change in receipt attributable only to compliers.

Deriving the Wald Ratio

Define the population assignment effect on the outcome, also called the reduced-form effect, as the difference in mean outcomes by assignment. Define the first-stage effect as the corresponding difference in mean treatment receipt:

$$ \Delta_Y = E[Y_i\mid Z_i=1]-E[Y_i\mid Z_i=0], \qquad \Delta_D = E[D_i\mid Z_i=1]-E[D_i\mid Z_i=0]. $$

By random assignment and consistency, the first contrast is the average difference between outcomes under assignment to the offer and assignment to control. By exclusion, those assignment-specific outcomes are \(Y_i(D_i(1))\) and \(Y_i(D_i(0))\). Therefore,

$$ \Delta_Y = E\!\left[Y_i(D_i(1))-Y_i(D_i(0))\right]. $$

Under monotonicity, each individual is an always-taker, never-taker, or complier. For an always-taker, receipt is 1 under either assignment, so their contribution to the outcome contrast is \(Y_i(1)-Y_i(1)=0\). For a never-taker, receipt is 0 under either assignment, so their contribution is \(Y_i(0)-Y_i(0)=0\). A complier's receipt changes from 0 to 1, so their contribution is \(Y_i(1)-Y_i(0)\). Thus only compliers contribute to the assignment-outcome contrast. This does not require always-takers or never-takers to have zero treatment effects; exclusion makes their outcomes unchanged by assignment because their receipt does not change.

Writing \(C_i\) for the indicator that individual \(i\) is a complier, the contrast can be written as

$$ \Delta_Y = E\!\left[C_i\{Y_i(1)-Y_i(0)\}\right] = P(C_i=1)\,E\!\left[Y_i(1)-Y_i(0)\mid C_i=1\right] = P(C_i=1)\tau_C. $$

The first-stage contrast follows the same type-by-type reasoning. Always-takers receive treatment under both assignments, and never-takers receive it under neither. Compliers alone change receipt from 0 to 1. Consequently,

$$ \Delta_D = E[D_i(1)-D_i(0)] = P(C_i=1). $$

When the first stage is positive, divide the outcome contrast by the receipt contrast. The complier share cancels:

$$ \frac{\Delta_Y}{\Delta_D} = \frac{P(C_i=1)\tau_C}{P(C_i=1)} =\tau_C. $$
Theorem: Under random assignment, consistency and SUTVA, the exclusion restriction, monotonicity, and a positive first stage, the ratio of the population assignment effect on the outcome to the population assignment effect on treatment receipt identifies the complier average causal effect: $$ \tau_C = \frac{E[Y_i\mid Z_i=1]-E[Y_i\mid Z_i=0]} {E[D_i\mid Z_i=1]-E[D_i\mid Z_i=0]}. $$

Worked Example: Seeing the Complier Share Cancel

Consider a hypothetical population with 1,000 individuals: 200 compliers, 500 always-takers, and 300 never-takers. Suppose the mean potential outcomes for compliers are \(E[Y_i(0)\mid C_i=1]=10\) and \(E[Y_i(1)\mid C_i=1]=14\), in outcome units. Among always-takers, suppose the potential outcome means are 8 under control receipt and 20 under treatment receipt. Among never-takers, suppose they are 5 and 9, respectively. Assume random assignment, exclusion, and monotonicity.

The complier share is \(200/1000=0.20\), and the CACE is \(14-10=4\) outcome units. To obtain the assignment-outcome contrast, compare expected mean outcomes under the two assignments. Under \(Z=1\), compliers receive treatment, always-takers receive treatment, and never-takers do not:

$$ E[Y_i\mid Z_i=1] =0.20(14)+0.50(20)+0.30(5) =2.8+10+1.5=14.3. $$

Under \(Z=0\), compliers do not receive treatment, while always-takers and never-takers retain their usual receipt:

$$ E[Y_i\mid Z_i=0] =0.20(10)+0.50(20)+0.30(5) =2+10+1.5=13.5. $$

Thus \(\Delta_Y=14.3-13.5=0.8\) outcome units. The receipt rates under the two assignments are \(0.20+0.50=0.70\) and \(0.50\), so \(\Delta_D=0.20\). The ratio is \(0.8/0.20=4\) outcome units per unit of treatment receipt, which equals the CACE. The treatment effects among always-takers and never-takers need not be zero: the specified effects are \(20-8=12\) and \(9-5=4\). They contribute zero to the assignment contrast because their treatment receipt does not change with assignment.

From Identification to a Sample Estimate

In data, the population contrasts are unknown. A common estimator replaces each population mean with its observed sample mean in the relevant assignment group. If \(\bar{Y}_{Z=1}\) and \(\bar{Y}_{Z=0}\) denote the sample outcome means, and \(\bar{D}_{Z=1}\) and \(\bar{D}_{Z=0}\) the sample receipt means, the sample Wald estimator is

$$ \widehat{\tau}_{W} = \frac{\bar{Y}_{Z=1}-\bar{Y}_{Z=0}} {\bar{D}_{Z=1}-\bar{D}_{Z=0}}. $$

This is an estimate of the identified population CACE, not generally the exact CACE in a finite sample. A nonzero sample denominator is needed to calculate it, and a small denominator can make the estimate unstable. The assumptions justify the population target; randomization alone does not establish exclusion or monotonicity.

Worked Example: Calculating a Sample Wald Estimate

In a hypothetical randomized encouragement study, 300 participants are assigned to the offer and 300 to control. The observed mean outcome is 12.4 units in the offer group and 11.2 units in the control group. Treatment receipt rates are 0.72 and 0.52, respectively. Suppose the design supports random assignment and, for this example, exclusion and monotonicity are assumed.

The sample reduced-form difference is

$$ \bar{Y}_{Z=1}-\bar{Y}_{Z=0} =12.4-11.2=1.2\text{ outcome units}. $$

The sample first stage is

$$ \bar{D}_{Z=1}-\bar{D}_{Z=0} =0.72-0.52=0.20. $$

Therefore,

$$ \widehat{\tau}_{W} =\frac{1.2}{0.20}=6.0\text{ outcome units}. $$

The estimate says that the estimated average treatment effect for compliers is 6.0 outcome units. It does not say that the assignment effect is 6.0 units: the observed assignment effect is 1.2 units. Dividing by the 0.20 receipt difference scales that assignment effect to the complier effect under the stated assumptions. The group summaries alone cannot verify exclusion or monotonicity.

Worked Example: A Binary Outcome and Percentage-Point Effects

Consider a hypothetical randomized study with a binary outcome, such as whether an event occurred. Suppose the population comprises 40% compliers, 20% always-takers, and 40% never-takers. Among compliers, the event probability under control receipt is 0.30 and under treatment receipt is 0.40. Suppose the outcome probability for always-takers under treatment receipt is 0.60, and for never-takers under control receipt is 0.20. Assume random assignment, exclusion, and monotonicity.

The complier effect is \(0.40-0.30=0.10\), or 10 percentage points. Under assignment to the offer, the complier outcome probability is 0.40, the always-taker probability is 0.60, and the never-taker probability is 0.20. The overall mean is

$$ E[Y_i\mid Z_i=1] =0.40(0.40)+0.20(0.60)+0.40(0.20) =0.16+0.12+0.08=0.36. $$

Under control assignment, compliers instead have outcome probability 0.30, while the other two groups' receipt remains unchanged:

$$ E[Y_i\mid Z_i=0] =0.40(0.30)+0.20(0.60)+0.40(0.20) =0.12+0.12+0.08=0.32. $$

The outcome contrast is \(0.36-0.32=0.04\), or 4 percentage points. The receipt rates are \(0.40+0.20=0.60\) under the offer and \(0.20\) under control, giving a first stage of \(0.40\). Hence the Wald ratio is \(0.04/0.40=0.10\), or 10 percentage points. The outcome scale is preserved by the ratio: a binary-outcome CACE is a difference in probabilities, not a probability that an individual benefits.

Common Mistakes and Interpretation

  • Calling the Wald ratio the overall average treatment effect. The derivation divides out the complier share; it does not make the complier effect representative of always-takers, never-takers, or the full population.
  • Assuming exclusion means no treatment effect for noncompliers. Exclusion says assignment affects outcomes only through receipt. Always-takers and never-takers have no assignment-outcome contrast because their receipt is unchanged. Their outcomes under treatment and control may still differ.
  • Confusing assignment with receipt. The numerator compares outcomes by randomized assignment; the denominator compares receipt by assignment. A direct comparison by observed treatment receipt is not the Wald ratio and is not protected by randomization in the same way.
  • Ignoring the first stage. If assignment does not change treatment receipt in the population, the denominator is zero and this ratio does not identify a CACE. In a sample, a very small estimated first stage can also make the ratio imprecise.
  • Treating the assumptions as consequences of randomization. Randomization supports the assignment contrasts. Exclusion and monotonicity are additional substantive assumptions, not automatic features of a randomized design.

The Wald result is valuable because it gives a causal interpretation to a ratio of two assignment contrasts when actual treatment receipt is imperfectly controlled by assignment. Its validity depends on the target population and assumptions, not merely on the arithmetic. The numerator and denominator should therefore be reported and interpreted alongside the ratio, with outcome and treatment-receipt units stated clearly.

Check Your Understanding

Answer each question by referring to the potential-outcomes derivation.

  1. Under monotonicity, which compliance types contribute to the first-stage difference, and why?
  2. Why does an always-taker's contribution to the assignment-outcome contrast equal zero under exclusion, even if their treatment effect is nonzero?
  3. If the population reduced-form effect is 0.9 outcome units and the first stage is 0.30, what is the Wald ratio, and what population effect does it target?
  4. Does random assignment by itself guarantee the exclusion restriction? Explain.
  5. What does a zero population first stage imply for the Wald identification formula?
Clinical Biostats